Ramachandran R, Klufas A S, Molino M, Ahuja M, Hoxie J A, Brass L F
Department of Medicine of the University of Pennsylvania, Philadelphia, 19104, USA.
Thromb Haemost. 1997 Sep;78(3):1119-24.
Platelet activation by thrombin is at least partially mediated by a G-protein-coupled receptor whose extended N-terminus is cleaved by thrombin. Theoretically, this should release a small fragment containing the original receptor N-terminus. However, the fate of this fragment is unknown, as is its biological role, if any. To begin to examine these issues, we have prepared monoclonal anti-receptor antibodies whose epitopes lie entirely N-terminal to the thrombin cleavage site. By flow cytometry and fluorescence microscopy of human platelets and megakaryoblastic CHRF-288 cells, these antibodies were found to recognize intact receptors and receptors activated by the agonist peptide, SFLLRN, but not receptors whose N-terminus had been cleaved by thrombin or cathepsin G. Incubating CHRF-288 cells with thrombin released pre-bound antibody from the cell surface. An assay based upon the antibodies was able to detect a fragment containing the original receptor N-terminus in the supernate of thrombin-treated human platelets. The concentration of the fragment obtained with platelets from 15 normal donors was 4.8 +/- 0.9 pmol per 10(9) platelets (mean +/- sem), which is similar to the value expected if all of the thrombin receptors present on human platelets have been cleaved. Taken together, these results demonstrate that 1) following receptor cleavage a fragment containing the original N-terminus of the receptor is released from the platelet surface, 2) based upon epitope mapping, this fragment is at least 15-20 residues long, 3) it is possible to quantitate the receptor fragment in the supernates of cells exposed to thrombin, and 4) the results of the quantitation suggest that on platelets all of the receptors have been cleaved and 100% of the fragment is present in the cell supernate. Depending on it survival time, measurements of the receptor fragment in blood or urine samples may eventually prove to be a useful marker for thrombin receptor activation in vivo.
凝血酶介导的血小板激活至少部分是由一种G蛋白偶联受体介导的,该受体的延长N端被凝血酶切割。理论上,这应该会释放出一个包含原始受体N端的小片段。然而,这个片段的命运尚不清楚,其生物学作用(如果有的话)也不清楚。为了开始研究这些问题,我们制备了单克隆抗受体抗体,其表位完全位于凝血酶切割位点的N端。通过对人血小板和巨核母细胞CHRF-288细胞进行流式细胞术和荧光显微镜观察,发现这些抗体能够识别完整的受体和被激动剂肽SFLLRN激活的受体,但不能识别N端已被凝血酶或组织蛋白酶G切割的受体。用凝血酶孵育CHRF-288细胞会使预先结合的抗体从细胞表面释放出来。基于这些抗体的检测方法能够在凝血酶处理的人血小板的上清液中检测到一个包含原始受体N端的片段。来自15名正常供体的血小板获得的片段浓度为每10^9个血小板4.8±0.9 pmol(平均值±标准误),这与如果人血小板上所有的凝血酶受体都被切割时预期的值相似。综上所述,这些结果表明:1)受体切割后,一个包含受体原始N端的片段从血小板表面释放出来;2)基于表位作图,这个片段至少有15 - 20个残基长;3)可以对暴露于凝血酶的细胞上清液中的受体片段进行定量;4)定量结果表明血小板上所有的受体都已被切割,并且100%的片段存在于细胞上清液中。根据其存活时间,检测血液或尿液样本中的受体片段最终可能被证明是体内凝血酶受体激活的一个有用标志物。